NCT00770510
A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)
See it on ClinicalTrials.gov ↗72 people
40.3%
59.7%
29 womenmiddle line = equal numbers43 men
- Phase
- PHASE2, PHASE3
- Paid for by
- Eisai Co., Ltd.
- Finished
- 2010-05
- Health conditions
- Primary Insomnia
- Who could join
- Anyone
- Ages
- 21 Years – 64 Years
- Average age
- mean 39.4 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 64 Years.”
- No mental health conditions
Women with depression, bipolar disorder or other mental health conditions were turned away.
“Participants with comorbid sleep disorder associated with other disease(s) such as psychiatric and/or physical disease(s).”
Study titles and rules are shown in their original English.